70 emerging market countries in July 2023 and North America in September 2023 , the full transition of Viatris ’ biosimilars operations to Biocon Biologics in Europe represents another significant milestone as a worldleading biosimilars company . In Europe , Biocon Biologics portfolio includes 7 biosimilars : Insulin Aspart and Insulin Glargine , Bevacizumab , Pegfilgrastim , Trastuzumab , Adalimumab , and Etanercept . At a global level , Biocon Biologics has a robust pipeline of 20 assets for diabetology , oncology , immunology , ophthalmology , and bone health . Serving over 5.7M patients annually , the the company is providing access to high-quality therapies and solutions to patients , healthcare systems and governments across the globe .
Indian Immunologicals launches Measles & Rubella vaccine
Human Biologicals Institute ( HBI ), a division of Indian Immunologicals Limited ( IIL ) launched the Mabella ( Measles and Rubella ) vaccine for children . This live attenuated MR vaccine has been developed by IIL in an exclusive partnership with Polyvac Institute , Vietnam . Through extensive human clinical trials , Mabella has been proven to be safe and effective . Established in 1998 , IIL celebrated its silver jubilee , with distinguished medical doctors from various parts of the country assembled in the serene precincts of Udhagamandalam ( Ooty ).
Upon request from Government of India , HBI indigenously developed India ’ s 1st safe Vero-cell rabies vaccine – Abhayrab in 1998 , paving way for Government of India to phase out the painful nerve tissue vaccine . Today , Abhayrab is the largest selling Anti-Rabies vaccine in the world . Millions of lives have been saved in India and across the world with HBI ’ s Abhayrab vaccine . Subsequently , several childhood vaccines such as DPT , Pentavalent Vaccine , TT , Hepatitis-B , MR , Td vaccines were introduced by HBI .
BioTech
BIOVOICENEWS . COM 51